Next Article in Journal
Transcriptome Analysis of C. elegans Reveals Novel Targets for DON Cytotoxicity
Next Article in Special Issue
Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii
Previous Article in Journal
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
Previous Article in Special Issue
Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(7), 261; https://doi.org/10.3390/toxins10070261

Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells

1
Structural and Molecular Biology, Division of Biosciences, Faculty of Life Sciences, University College London, London WC1E 6BT, UK
2
Department of Biomedical Science, University of Sheffield, Firth Court, Western Bank, Sheffield S10 2TN, UK
3
Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK
*
Authors to whom correspondence should be addressed.
Received: 18 May 2018 / Revised: 15 June 2018 / Accepted: 20 June 2018 / Published: 27 June 2018
(This article belongs to the Special Issue Venom and Toxin as Targeted Therapy)
Full-Text   |   PDF [2762 KB, uploaded 27 June 2018]   |  

Abstract

Immunotoxins are being investigated as anti-cancer therapies and consist of a cytotoxic enzyme fused to a cancer targeting antibody. All currently used toxins function via the inhibition of protein synthesis, making them highly potent in both healthy and transformed cells. This non-specific cell killing mechanism causes dose-limiting side effects that can severely limit the potential of immunotoxin therapy. In this study, the recently characterised bacterial toxin Burkholderia lethal factor 1 (BLF1) is investigated as a possible alternative payload for targeted toxin therapy in the treatment of neuroblastoma. BLF1 inhibits translation initiation by inactivation of eukaryotic initiation translation factor 4A (eIF4A), a putative anti-cancer target that has been shown to regulate a number of oncogenic proteins at the translational level. We show that cellular delivery of BLF1 selectively induces apoptosis in neuroblastoma cells that display MYCN amplification but has little effect on non-transformed cells. Future immunotoxins based on this enzyme may therefore have higher specificity towards MYCN-amplified cancer cells than more conventional ribosome-inactivating proteins, leading to an increased therapeutic window and decreased side effects. View Full-Text
Keywords: ribosome-inactivating protein; BLF1; eIF4A; MYCN; cancer; neuroblastoma; apoptosis ribosome-inactivating protein; BLF1; eIF4A; MYCN; cancer; neuroblastoma; apoptosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Rust, A.; Shah, S.; Hautbergue, G.M.; Davletov, B. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells. Toxins 2018, 10, 261.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top